Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Brisotto

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Current Medicinal Chemistry|June 8, 2018
Emerging Technologies for Cancer Research: Towards Personalized Medicine with Microfluidic Platforms and 3D Tumor ModelsMatteo Turetta, Fabio Del Ben, Giulia Brisotto, et al.
Frontiers in Oncology|September 9, 2022
Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patientsElena Muraro, Fabio Del Ben, Matteo Turetta, et al.
Biomedicines|January 26, 2024
Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's LymphomaValli De Re, Egesta Lopci, Giulia Brisotto, et al.
Frontiers in Oncology|September 26, 2024
The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancerSilvio Ken Garattini, Debora Basile, Valli' De Re, et al.
Cancers|August 17, 2018
Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor CellsMatteo Turetta, Michela Bulfoni, Giulia Brisotto, et al.
The Prostate|September 6, 2024
Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapyFabio Matrone, Fabio Del Ben, Marcella Montico, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 10, 2021
IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workersGiulia Brisotto, Elena Muraro, Marcella Montico, et al.
Cell Death and Differentiation|April 19, 2018
A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
International Journal of Molecular Sciences|December 16, 2020
Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic OptionsValli De Re, Giulia Brisotto, Ombretta Repetto, et al.
Cell Death and Differentiation|February 8, 2019
Correction to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Current Medicinal Chemistry|June 8, 2018
Emerging Technologies for Cancer Research: Towards Personalized Medicine with Microfluidic Platforms and 3D Tumor ModelsMatteo Turetta, Fabio Del Ben, Giulia Brisotto, et al.
Frontiers in Oncology|September 9, 2022
Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patientsElena Muraro, Fabio Del Ben, Matteo Turetta, et al.
Biomedicines|January 26, 2024
Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's LymphomaValli De Re, Egesta Lopci, Giulia Brisotto, et al.
Frontiers in Oncology|September 26, 2024
The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancerSilvio Ken Garattini, Debora Basile, Valli' De Re, et al.
Cancers|August 17, 2018
Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor CellsMatteo Turetta, Michela Bulfoni, Giulia Brisotto, et al.
The Prostate|September 6, 2024
Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapyFabio Matrone, Fabio Del Ben, Marcella Montico, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 10, 2021
IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workersGiulia Brisotto, Elena Muraro, Marcella Montico, et al.
Cell Death and Differentiation|April 19, 2018
A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
International Journal of Molecular Sciences|December 16, 2020
Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic OptionsValli De Re, Giulia Brisotto, Ombretta Repetto, et al.
Cell Death and Differentiation|February 8, 2019
Correction to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
Pageof 3